Xiralite-Scan in detecting early psoriatic arthritis

Recruiting

• Conditions: L40.5; L40.0; Arthropathic psoriasis; Psoriasis vulgaris

• Registration Number: DRKS00005799
• Lead Sponsor: Fraunhofer IMEProjektgruppe TMPc/o Universitätsklinikum Frankurt/Main

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-04-07
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

Psoriasis vulgaris (dermatologic proven), risk of a muculoscelettal manifestation defined as nail psoriasis and/or musculoscelettal pain and/or swollen joints within 6 months, no known Psoriatic Arthritis, no biological therapy

Exclusion Criteria

known hypersensitivity against immunofluorescence-contrast agent, esp. ICG, wounds at hands, allergy against iodine, manifest hyperthyreosis, autonomy of thyroid adenomas, focal and diffuse thyroid autonomy, presence of a significant co-morbidity or severe and/or uncontrolled disease, that would effect patients safety and collide with results of the study

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
non-inferiority of fluorescence-optical imaging to physical examination and ultrasound in detection of Psoriatic Arthritis out of Psoriasis Patients

Secondary Outcome Measures

Name	Time	Method
Comparison of fluorescence-optical imaging to early-diagnosis questionnaires, physical examination and ultrasound in early detection of Psoriatic Arthrtitis